Latest Tuberculosis treatment Stories
Health officials in New Zealand are looking for anyone who may have been exposed to a woman with an aggressive form of tuberculosis.
By Graeme Hetherington A DOCTOR is working with HIV and TB patients in the remote heart of Africa with the support of a North-East charity.
LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008.
By Aggarwal, Deepak Mohapatra, P R; Rekha, V V Banu; Balasubramanian, R; Swaminathan, S; Ramachandran, R; Rahman, F; Sundaram, V; Thyagarajan, K; Selvakumar, N; Adhilakshmi, A R; Iliayas, S; Narayanan, P R Sir, Banu Rekha and colleagues' in their study found that at the end of intensive phase of tuberculosis treatment among sputum positive cases, the smear conversion rates were 58, 61, 62 per cent and culture conversion 86, 88 and 92 per cent respectively.
Aggressive treatment involving a combination of drugs may be the cure for extensively drug-resistant tuberculosis, researchers report.
In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB.
WALTHAM, Mass., Aug. 8 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. , a leading provider of near-patient diagnostics, monitoring and health management solutions, is featuring its new TB diagnostic test, the Clearview TB ELISA, at the International AIDS conference (AIDS 2008).
Extensively drug-resistant tuberculosis, or XDR-TB, can be commuted in an individualized outpatient therapy program, researchers in Peru said.
By Ben Guy MAIL workers were offered TB screening after two staff at a Tyneside sorting office caught the deadly disease.
Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today are presenting detailed results from the companies' 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease at the Alzheimer's Association's International Conference on Alzheimer's Disease 2008 in Chicago, Illinois.
- The act of sweetening by admixture of some saccharine substance.